Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ligand Pharm (NQ: LGND )

122.55 -1.78 (-1.43%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ligand Pharm

< Previous 1 2 3 4 5 6 Next >
Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand’s Partner Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Pharma Updates Annual Guidance As It Spins Out Pelican Subsidiary
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) entered into a merger agreement under which its subsidiary, Pelican Technology Holdings Inc, has become a wholly owned subsidiary of Primrose Bio... 
Via Benzinga
Where Ligand Pharmaceuticals Stands With Analysts
Via Benzinga
Analyst Expectations for Ligand Pharmaceuticals's Future
Via Benzinga
Recap: Ligand Pharmaceuticals Q1 Earnings
Via Benzinga
Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Pharmaceuticals Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Reports Second Quarter 2023 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Pharmaceuticals Earnings Preview
Via Benzinga
Roth Capital Maintains Buy Rating for Ligand Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Ligand’s Collaborator Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand To Report Second Quarter 2023 Financial Results On August 8
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Why Are Novan Shares Nosediving Today?
Novan Inc (NASDAQ: NOVN) shares are trading lower after Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that it has offered to  
Via Benzinga
Ligand Offers $15 Million to Acquire Assets of Novan, Inc.
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection
From Novan, Inc.
Via GlobeNewswire
3 Stocks That Smart Investors Should Be Flocking to Now
Investors may want to detour away from the obvious trades and consider compelling top stocks for smart investors. 
Via InvestorPlace
Viking Therapeutics Outperforms Expectations: Analyst Increases Price Target Following Successful VK2809 Trial
Ligand Pharmaceuticals Incorporated's (NASDAQ: LGND) partner Viking Therapeutics Inc (NASDAQ: VKTX) announced positive topline results from its Phase 2b trial of VK2809 in  
Via Benzinga
Ligand’s Partner Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Reports First Quarter 2023 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand to Report First Quarter 2023 Financial Results on May 4, 2023
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Reports Fourth Quarter and Full Year 2022 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment
Via Benzinga
Ligand’s Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Earnings Scheduled For February 22, 2023
Companies Reporting Before The Bell • Rio Tinto (NYSE:RIO) is projected to report earnings for its Fiscal Year 2022. 
Via Benzinga
Ligand to Report Fourth Quarter Financial Results on February 22
From Ligand Pharmaceuticals Incorporated
Via Business Wire
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new... 
Via Benzinga
Ligand’s Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Tesla To $175? Here Are 10 Other Price Target Changes For Friday
Oppenheimer cut CarMax, Inc. (NYSE: KMX) price target from $100 to $75. . Oppenheimer analyst Brian Nagel maintained an Outperform rating on the stock. CarMax shares fell 1.3% to $56.47 in pre-market... 
Via Benzinga
Some 'Transgenic Animal Platforms Are More Than Equal,' Analyst Initiating Coverage On OmniAb Says
Credit Suisse initiated coverage on OmniAb Inc (NASDAQ: OABI) with an Outperform rating and a price target of $13. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.